HART

New York Life Investments Expands Its Dual Impact Lineup With The Launch Of Three Thematic ETFs

Retrieved on: 
Thursday, October 21, 2021
Woman, Efficiency, AAA, Twitter, EUR, Investment, Life, Insurance, United Kingdom, AUM, Instagram, National Wildlife Federation, National Wildlife, NWF, HART, Turtle, Research, Management, John Train (investment advisor), Fortune, Transport, ETF, Solution, New York Life Investments, Moody's Investors Service, NYSE, AHA, Social media, CEO, S&P Global Ratings, Movement, Environment, Girls Who Code, Student, Candriam Investors Group, Shark, Technology, LinkedIn, Conviction, American Heart Association, Family, ESG, Policy, Climate change, Biodiversity, Financial adviser, Renewable energy, Toy, Hunting, Aquaculture, Financial services

OCEN and CLNR's underlying indexes were both developed in collaboration with Candriam , a New York Life Investments company and pioneer in ESG investing and indexing.

Key Points: 
  • OCEN and CLNR's underlying indexes were both developed in collaboration with Candriam , a New York Life Investments company and pioneer in ESG investing and indexing.
  • "New York Life Investments' support will help Oceana's campaign teams continue to win policies that make our oceans more abundant and biodiverse.
  • Headquartered in New York City, New York Life's family of companies offers life insurance, retirement income, investments and long-term care insurance.
  • "New York Life Investments" is both a service mark, and the common trade name, of certain investment advisors affiliated with New York Life Insurance Company.

2022 Honda Passport is Ready for Stage Rally Competition

Retrieved on: 
Monday, October 18, 2021
SUV, American Rally Association, Honda Performance Development, Snow, Limited, Sequence, Maxxis, Dream, Quarter Midget racing, Racing Damashii, CarboTech, RAZR, Sport, Torque, Polycarbonate, Region, Multimedia, Racing, SOFR, Honda advanced technology, HART, ARA, Electronics, Honda Passport, OMP, Safety, Passport, V6, LSPR, HPD, Motor vehicle, Road

MARQUETTE, Mich., Oct. 18, 2021 /PRNewswire/ --A team of Honda engineers is taking the rugged new Honda Passport rally racing.

Key Points: 
  • MARQUETTE, Mich., Oct. 18, 2021 /PRNewswire/ --A team of Honda engineers is taking the rugged new Honda Passport rally racing.
  • Honda unveiled its 2022 Passport stage rally truck specially built for competition by the Honda Performance Development (HPD) Maxxis Rally racing team, highlighting the rugged capability and durability long engineered into Honda light trucks.
  • "We're ready to go racing with the rugged 2022 Honda Passport," said Honda engineer and co-driver Gabriel Nieves.
  • 2021 LSPR is the third stage rally event in which the team has competed in a Honda Passport.

Prevencio’s AI-driven HART CVE Blood Test Demonstrates Usefulness in Spinal Cord Injury Patients

Retrieved on: 
Monday, October 4, 2021
Technology, Medical Devices, Other Technology, Cardiology, Biotechnology, Other Health, Health, General Health, Data Management, Radiation, Cardiology, Algorithm, Diagnosis, Spinal cord injury, Congress, Machine learning, American College of Cardiology, Stroke, Veteran, Radiation exposure, HART, Patient, Artificial intelligence, Population, Physician, American Heart Association, Development, Heart, AI, Clinical Cardiology, Company, Biomarker, Cardiovascular disease, European Society of Cardiology, Risk, Atherosclerosis, Arrest, Degenerative disease, Journal, The American Journal of Cardiology, Framingham, Massachusetts, Risk assessment, Department, Medical device, Prevencio HART Tests, Prevencio, Inc., PREVENCIO HART TESTS, PREVENCIO, INC.

Prevencio, Inc. today announces the presentation of data acquired in patients with spinal cord injury demonstrating that its Artificial Intelligence (AI)-driven HART CVE blood test is useful, low risk and as accurate as currently used cardiac risk imaging tests that require radiation exposure.

Key Points: 
  • Prevencio, Inc. today announces the presentation of data acquired in patients with spinal cord injury demonstrating that its Artificial Intelligence (AI)-driven HART CVE blood test is useful, low risk and as accurate as currently used cardiac risk imaging tests that require radiation exposure.
  • Spinal cord injury patients have extremely sedentary lifestyles and, consequently, cardiac disease is highly prevalent, said William A. Bauman, M.D., Director of the Department of Veterans Affairs Rehabilitation Research & Development Services National Center for the Medical Consequences of Spinal Cord Injury.
  • We were pleased to find that Prevencios multiple protein HART CVE blood test proved to be a highly useful clinical tool demonstrating a relationship with coronary artery calcium scores and the Framingham scoring system to predict a cardiac event.
  • In the U.S., there are an estimated 291,000 people living with spinal cord injuries, about 40,000 of whom are veterans.

FLEXIM Announces New Non-Intrusive and Intrinsically Safe Explosion-Proof Flowmeter

Retrieved on: 
Friday, September 10, 2021

FLUXUS F/G831 has two intrinsically safe (Ex-ia) process inputs for connecting pressure and temperature sensors.

Key Points: 
  • FLUXUS F/G831 has two intrinsically safe (Ex-ia) process inputs for connecting pressure and temperature sensors.
  • This allows the transmitter to directly determine the output mass flow or standard volumetric flow rate.
  • At FLEXIM, transmitters and transducers are calibrated independently of each other in a patented process and without the influence of application-related disturbances.
  • Dr. Ingo Nickel, Head of Market Management Chemical Industry at FLEXIM, will present the new flowmeter series in a public webinar on Sept.23, 2021 (two sessions at 9a.m.

Prevencio’s Novel AI-Driven HART CADhs Blood Test Significantly More Accurate than Troponin for Obstructive Heart Disease

Retrieved on: 
Wednesday, September 1, 2021
Medical Devices, Health, Technology, Other Technology, Cardiology, Biotechnology, Company, Population, Degenerative disease, Massachusetts General Hospital, European Society of Cardiology, Journal, Congress, Technology, Computation, Diagnosis, Risk assessment, HART, Troponin, AUC, Machine learning, Algorithm, Cardiology, Cardiovascular disease, Death, Heart, AI, The American Journal of Cardiology, Hamburg, Biomarker, American College of Cardiology, Acute coronary syndrome, Risk, Adult, ESC, Patient, Clinical Cardiology, Arrest, American Heart Association, Stroke, Artificial intelligence, News, MD, Medical device, Medical imaging, Prevencio HART Tests, Prevencio, Inc., PREVENCIO HART TESTS, PREVENCIO, INC.

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.

Key Points: 
  • Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.
  • Cardiologists from University Heart Center of Hamburg Germany, Massachusetts General Hospital, and Inova Heart and Vascular Institute collaborated to test 924 patients for blood diagnosis of heart disease.
  • In addition to the HART CADhs blood test for heart disease and imminent risk of heart attack, Prevencio recently launched a second multiprotein blood test, HART CVE, for one-year risk of heart attack, stroke, or cardiac death.
  • Employing this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.

Anjelica B. Hart is recognized by Continental Who's Who

Retrieved on: 
Thursday, August 12, 2021
Online, Achievement Medal, HART, Multimedia, University of Phoenix, Parenting, Educational technology, Anxiety, The Chicago School of Professional Psychology, Community, Doctor of Education, Continental, Learning, Holism, Mental health, University, Chicago school, Technology, Trust (social science), Southern University, Behavior, Coaching, Educational psychology, Motivation, Bullying, Wiley College, Associate, Open educational resources, Medicine

SHREVEPORT, La., Aug. 12, 2021 /PRNewswire/ --Anjelica B. Hart is being recognized by Continental Who's Who as a Trusted Professional for her outstanding contributions in mental health and her unmatched dedication to her business Listening to My Hart.

Key Points: 
  • SHREVEPORT, La., Aug. 12, 2021 /PRNewswire/ --Anjelica B. Hart is being recognized by Continental Who's Who as a Trusted Professional for her outstanding contributions in mental health and her unmatched dedication to her business Listening to My Hart.
  • Having led an impressive nine-year career in the mental health field, Dr. Anjelica B. Hart is currently serving her community as a Professional and Personal Development Specialist.
  • She utilizes her educational background in psychology and professional mental health experience to assist others, especially members of the LGBTQ+ Community.
  • In hopes of educating, encouraging, and empowering people in need, Dr. Hart established her personal coaching and professional development business, Listening to My Hart, in July 2020.

Prevencio Announces U.S. Patent Issuance for Novel, Artificial Intelligence-driven Blood Test for Cardiac Risk

Retrieved on: 
Wednesday, August 4, 2021
Data Management, Medical Supplies, Health, Technology, Software, Cardiology, Biotechnology, Articles, Cybernetics, Academic disciplines, Emerging technologies, Artificial intelligence, Computational neuroscience, Machine learning, Heart, Cardiovascular disease, Prevencio HART Tests, Prevencio, Inc., PREVENCIO HART TESTS, PREVENCIO, INC.

Prevencio, Inc. today announces the United States Patent Offices issuance of a patent for its highly accurate blood test, HART CVE, for a patients one-year risk of heart attack, stroke, or cardiovascular death.

Key Points: 
  • Prevencio, Inc. today announces the United States Patent Offices issuance of a patent for its highly accurate blood test, HART CVE, for a patients one-year risk of heart attack, stroke, or cardiovascular death.
  • The company leveraged its Artificial Intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CVE.
  • This patent issuance for HART CVE demonstrates the U.S. Patent Offices recognition of our novel invention for a machine learning-driven, multiple protein, algorithmically scored blood test for detection of adverse cardiac events, said Rhonda Rhyne, President and Chief Executive Officer of Prevencio.
  • For additional information, visit Prevencio, Inc.
    Powered by Artificial Intelligence (AI), Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics.